A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Sunitinib
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 10 Apr 2012 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top